Knight Therapeutics (TSE:GUD)
TSX:GUD
Top Page
Knight Therapeutics
(TSX:GUD)
Select Model
Select Model
Rating:71Outperform
Price Target:
C$8.00
▲(7.38% Upside)
Action:UpgradedDate:03/21/26
The score is driven primarily by financial resilience (low leverage and improving cash generation) and a strong, guidance-raising earnings call. Technicals are supportive with price above key moving averages and positive MACD. The main offset is valuation risk stemming from negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Balance Sheet Strength
Knight's very low leverage and sizable equity base provide durable financial flexibility to fund launches, in-licenses and absorb operational setbacks without urgent refinancing. This structural strength supports strategic investments and risk absorption across multiple quarters.
Negative Factors
Brazil Regulatory Setback
A rejected marketing application and a potentially 14-month appeal materially delays access to the Brazilian market. Delays reduce near-to-medium-term revenue potential in a key LatAm geography and require management time and resources to remediate, raising execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Knight's very low leverage and sizable equity base provide durable financial flexibility to fund launches, in-licenses and absorb operational setbacks without urgent refinancing. This structural strength supports strategic investments and risk absorption across multiple quarters.
Read all positive factors
Knight Therapeutics (GUD) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$730.36M
Dividend YieldN/A
Average Volume (3M)48.52K
Price to Earnings (P/E)―
Beta (1Y)0.36
Revenue Growth18.70%
EPS Growth88.31%
CountryCA
Employees745
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.09
Shares Outstanding98,034,744
10 Day Avg. Volume49,308
30 Day Avg. Volume48,518
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)0.79
Price to Sales (P/S)1.34
P/FCF Ratio8.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$8.98Price Target Upside20.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.18
Revenue Forecast (FY)C$484.73M
Knight Therapeutics Business Overview & Revenue Model
Company Description
Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. I...
How the Company Makes Money
Knight Therapeutics makes money primarily by commercializing prescription pharmaceuticals that it has acquired or licensed. Revenue is generated mainly from product sales to customers (e.g., wholesalers, hospitals, pharmacies, and other healthcare...
Knight Therapeutics Earnings Call Summary
Earnings Call Date:Nov 06, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
Knight Therapeutics reported strong financial performance with record revenues and EBITDA, significant growth driven by key products, and an improved financial outlook for 2025. The expansion of the oncology portfolio and increased credit facility provide a solid foundation for future growth. However, challenges were noted with regulatory setbacks in Brazil and Canada and a financial asset loss, though these do not overshadow the overall positive trends and achievements.Positive Updates
Record High Adjusted Revenues and EBITDA
Knight Therapeutics achieved record high adjusted revenues of $319 million and adjusted EBITDA of approximately $49 million for the nine months ended September 30, 2025. Revenues grew by $48 million or 18% compared to the same period last year.
Negative Updates
Rejection of Marketing Authorization in Brazil
Knight received a rejection of its marketing authorization application for TAVALISSE from Anvisa, the Brazilian Health Agency. An appeal has been submitted, which could take up to 14 months.
Read all updates
Q3-2025 Updates
Positive
Negative
Record High Adjusted Revenues and EBITDA
Knight Therapeutics achieved record high adjusted revenues of $319 million and adjusted EBITDA of approximately $49 million for the nine months ended September 30, 2025. Revenues grew by $48 million or 18% compared to the same period last year.
Read all positive updates
Company Guidance
In the third quarter of 2025, Knight Therapeutics reported record adjusted revenues of $122.6 million, marking a 34% increase over the same period last year, with a constant currency revenue growth of 31%. The company achieved an adjusted EBITDA of $21 million, a 56% rise from the previous year, and an adjusted EBITDA per share increase of 62% to $0.21. This growth was driven by the Paladin and Sumitomo transactions, which contributed $25 million in incremental revenues, and a 15% increase in key oncology products like AKYNZEO and MINJUVI. The company also saw a 127% increase in revenues within its specialty therapeutic area, largely due to the Paladin and Sumitomo portfolios. Despite setbacks with regulatory approvals in Brazil and Canada, Knight aims to address these and has raised its 2025 revenue guidance to between $430 million and $440 million, with an adjusted EBITDA margin of 13.5% to 14.5%.Knight Therapeutics Financial Statement Overview
Summary
Income Statement
57
Neutral
Balance Sheet
82
Very Positive
Cash Flow
74
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 450.09M | 371.30M | 328.20M | 293.56M | 243.48M |
| Gross Profit | 150.74M | 174.41M | 152.65M | 138.06M | 115.41M |
| EBITDA | 54.37M | 64.38M | 40.90M | 25.26M | 42.59M |
| Net Income | -5.37M | 4.33M | -16.84M | -29.89M | 15.68M |
Balance Sheet | |||||
| Total Assets | 1.05B | 963.80M | 945.49M | 1.05B | 991.89M |
| Cash, Cash Equivalents and Short-Term Investments | 95.28M | 172.84M | 154.42M | 185.61M | 162.99M |
| Total Debt | 77.91M | 49.46M | 69.09M | 77.70M | 40.96M |
| Total Liabilities | 279.03M | 168.69M | 198.62M | 228.98M | 149.87M |
| Stockholders Equity | 767.27M | 795.11M | 746.87M | 825.86M | 842.02M |
Cash Flow | |||||
| Free Cash Flow | 68.40M | 4.81M | 25.98M | 14.66M | -179.56M |
| Operating Cash Flow | 70.30M | 36.28M | 35.94M | 40.48M | 44.62M |
| Investing Cash Flow | -84.11M | 16.96M | 29.34M | -63.08M | -105.28M |
| Financing Cash Flow | 13.01M | -33.54M | -81.00M | 1.76M | -78.31M |
Knight Therapeutics Technical Analysis
Positive
7.45
Price Trends
6.32
Positive
6.17
Positive
6.13
Positive
Market Momentum
0.33
Negative
82.23
Negative
94.96
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GUD, the sentiment is Positive. The current price of 7.45 is above the 20-day moving average (MA) of 6.64, above the 50-day MA of 6.32, and above the 200-day MA of 6.13, indicating a bullish trend. The MACD of 0.33 indicates Negative momentum. The RSI at 82.23 is Negative, neither overbought nor oversold. The STOCH value of 94.96 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:GUD.
Knight Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | C$475.29M | 10.05 | 24.23% | ― | 94.28% | 5.23% | |
71 Outperform | C$730.36M | -112.09 | -0.45% | ― | 18.70% | 88.31% | |
61 Neutral | C$1.33B | -104.58 | -0.87% | ― | 22.20% | ― | |
54 Neutral | C$261.77M | 3.90 | 4.86% | ― | 62.15% | 60.50% | |
52 Neutral | C$271.64M | 44.94 | -7.78% | ― | 23.87% | -19.57% | |
52 Neutral | C$137.60M | -8.75 | -19.40% | ― | 0.73% | 33.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
TSE:GUD
Knight Therapeutics
7.45
1.76
30.93%
TSE:CPH
Cipher Pharmaceuticals
18.80
7.17
61.65%
TSE:OGI
Organigram Global
1.92
0.58
43.28%
TSE:ACB
Aurora Cannabis
4.79
-0.96
-16.70%
TSE:CRON
Cronos Group
3.52
1.15
48.52%
TSE:HLS
HLS Therapeutics Inc
4.40
0.25
6.02%
Knight Therapeutics Corporate Events
Business Operations and StrategyStock BuybackFinancial DisclosuresPrivate Placements and Financing
Knight Therapeutics Posts Record 2025 Revenue, Sets Confident 2026 Outlook
Positive
Mar 19, 2026
Knight Therapeutics reported record 2025 revenues of $450.1 million and its highest-ever adjusted EBITDA and operating cash flow since inception, driven largely by contributions from the Paladin and Sumitomo acquisitions and strong growth in key p...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.